Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. - Wikidata - awgldk - TriplyDB

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.

http://www.wikidata.org/entity/Q36526999

about

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Evasion of host immune defenses by human papillomavirus Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.Kynurenine and uric acid levels in chronic myeloid leukemia patients.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.Immunotherapeutic approaches to treat multiple myeloma Recent advances on cellular therapies and immune modulators for graft-versus-host disease.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents.Discovery and application of immune biomarkers for hematological malignancies.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Targeting Leukemia Stem Cells in the Bone Marrow Niche.Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia.Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.Long noncoding RNA lnc-sox5 modulates CRC tumorigenesis by unbalancing tumor microenvironment.

P2860

Q27010234-FE0EB885-64E8-4C9D-8D1F-57994D79C9FA Q28067817-A79210CD-DFF3-4B2B-9D1C-1FBF95A8C11F Q28076194-9CCC4E55-E515-46C9-9B50-CE6798B77C82 Q33688517-2D1C23AD-00CA-4338-B66A-127F35F90D73 Q34655638-53CB766E-AEAD-4586-AC37-E12CB01DFC5D Q35507380-B20D8AAE-9B02-4F4C-8D88-BEF79A8A02AE Q35600095-2B4E38A7-DB6B-4CD5-9BA5-36BDA94FE280 Q35623772-83A37945-81ED-46B1-B09F-CCABB91CFE1B Q38155039-2D6DB1A6-FF0F-4A7D-8367-EF89F3CCDD82 Q38171067-5ECA587E-9514-45DA-834B-A678FE2EBC8B Q38246755-7B10ACC4-DBB9-4DB2-BFF4-137221C17B0A Q38526452-6EFC5ADC-91BC-4D10-AE02-715A37699BE1 Q38704573-3A6CD723-15BD-4B9F-B89F-0D9C40C45B4D Q41149149-BA31D738-8122-4CC5-BA5A-7A0941BE71BF Q41919734-65C45E45-D9A1-4935-A26C-3C6A276F709B Q47681393-410B6585-F293-422C-94C7-422C018B53FF Q49830211-A62A6383-E305-43E4-A6B3-8AB0D4054BF1 Q52375473-4D61E850-CB4E-41BA-A000-472FB18A223B Q53122380-4D2275B5-C521-4AFB-8F53-2DE15E6E0068 Q54213159-E0AB0320-A408-42C1-AAE3-1C5974923547 Q55424846-C5084973-05FA-49C5-A529-70C0E3B1381A

P2860

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.

http://www.wikidata.org/entity/Q36526999

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Indoleamine 2,3-dioxygenase 1 ...... rmalities in multiple myeloma.

@ast

Indoleamine 2,3-dioxygenase 1 ...... rmalities in multiple myeloma.

@en

type

label

Indoleamine 2,3-dioxygenase 1 ...... rmalities in multiple myeloma.

@ast

Indoleamine 2,3-dioxygenase 1 ...... rmalities in multiple myeloma.

@en

prefLabel

Indoleamine 2,3-dioxygenase 1 ...... rmalities in multiple myeloma.

@ast

Indoleamine 2,3-dioxygenase 1 ...... rmalities in multiple myeloma.

@en

P1433

Q36526999-C7B13CAA-7DC5-48E0-A3CA-A9E67EB7C977

P1476

Q36526999-BCAB345E-7DCE-46E0-8872-FDEECC81EB16

P2093

Q36526999-5294D17D-9153-40BB-A1D1-6D50E27831C8

Q36526999-7ED0BEBB-E4AC-4DCA-A597-C5A774185E10

Q36526999-8B7375C0-EF94-4E59-9739-A6ADAA87FC79

Q36526999-8F2433DC-7887-4E44-AA47-3DD5777AA109

Q36526999-94CCBDEF-6642-4D77-9056-E985DCCB53BB

Q36526999-A5BF13CA-858F-47F3-B7DB-9A477774C137

Q36526999-A9FDDE17-44B6-4901-A553-6AF1DFA9E2F9

Q36526999-B695E4C8-D259-4179-B5D8-EA60B5CA85D6

Q36526999-C1E40767-9A64-4DAF-AE33-88510634EC85

Q36526999-DD1D456D-7967-45D9-ABB7-2C70878E66D7

P2860

Q36526999-005F84CE-262F-47BB-8D51-25C974BE866D

Q36526999-042C624D-4922-4A8B-9F54-B89C00D05000

Q36526999-04658BE2-BA9E-4A82-A34D-01FF99D78C70

Q36526999-078A90F9-8CBB-4F45-892A-E4100A72549B

Q36526999-0CFC63A0-205F-4762-9EA3-3BB33C2FCC3A

Q36526999-17A3D3E4-DC85-4954-897A-AF2CE0E5CEFC

Q36526999-18F7E5EB-67BA-4D8B-A54B-1ABA55552EBF

Q36526999-191A1C0F-A33A-4E90-A364-952F1A7DB643

Q36526999-1B017D4A-7365-4ED4-9BFD-8D826051ADE2

Q36526999-1E96DAF6-DA40-4209-88F2-061524152CAC

P2888

Q36526999-D286BE4B-81FC-433A-BB50-618B91C0D0E7

P304

Q36526999-DF4EBAC1-C4B0-4EEF-BCDB-669088055A35

P31

Q36526999-101BBDF4-FF4A-4D3B-8EA4-BCC939329872

P356

Q36526999-2D30358D-2C3B-4F39-88FF-B7F9A382A412

P478

Q36526999-58094071-B1A1-43E4-835D-45700C88693D

P50

Q36526999-2BB0AF9B-9CCA-4D22-BBA7-6BE487D3C644

Q36526999-BD2B9915-E4E0-4EA5-9A1F-839E2AEB688B

Q36526999-CFCDB938-0015-49D6-A415-0B21A9CF4410

Q36526999-FE3F791D-F044-4271-BA04-C57E4A763D58

P577

Q36526999-E841EF56-9AC8-4856-A6F1-0B2683F0BED6

P5875

Q36526999-27405C00-7566-4810-9204-04304D68C306

P6179

Q36526999-C354AA25-F3DE-4535-A37E-9935E61C5FB5

P698

Q36526999-5081848C-05E1-45F4-9381-C926766B7B0F

P932

Q36526999-60948DE8-04AF-481B-8F35-A81399EFB435

P356

1479-5876-10-247

P1433

Journal of Translational Medicine

P1476

Indoleamine 2,3-dioxygenase 1 ...... ormalities in multiple myeloma

@en

P2093

Alberto Rocci

http://www.w3.org/2001/XMLSchema#string

Andrea Mariotti

http://www.w3.org/2001/XMLSchema#string

Annabella Procoli

http://www.w3.org/2001/XMLSchema#string

Daniela Natale

http://www.w3.org/2001/XMLSchema#string

Franco Locatelli

http://www.w3.org/2001/XMLSchema#string

Giovanni Scambia

http://www.w3.org/2001/XMLSchema#string

Giuseppina Bonanno

http://www.w3.org/2001/XMLSchema#string

Ignazio Majolino

http://www.w3.org/2001/XMLSchema#string

Linda Novarese

http://www.w3.org/2001/XMLSchema#string

Luca De Rosa

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase

Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation

FOXP3+ regulatory T cells in the human immune system

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

P2888

1479-5876-10-247

P304

247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-10-247

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Raimondo De Cristofaro

Valentina Folgiero

Antonio Palumbo

P577

2012-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233900586

http://www.w3.org/2001/XMLSchema#string

P6179

1052189739

http://www.w3.org/2001/XMLSchema#string

P698

23232072

http://www.w3.org/2001/XMLSchema#string

P932

3543251

http://www.w3.org/2001/XMLSchema#string